Ingevity sees FY24 revenue $1.40B, consensus $1.42B

Sees FY25 adjusted EBITDA of $360M and free cash flow above $40M. “We are pleased to announce that our full year Adjusted EBITDA is expected to reach the high end of our previous guidance and free cash flow to significantly exceed prior guidance. This achievement is driven by the ongoing positive impact of our Performance Chemicals segment repositioning and the consistent strong performance of our Performance Materials segment, which has delivered another robust quarter. With this positive momentum, we have increased confidence in our ability to deliver slightly above $400 million of Adjusted EBITDA in 2025,” said CEO Fernandez-Moreno. “We will provide more detail on our 2025 guidance at our upcoming Q4 and FY24 earnings call scheduled on February 19, 2025.”